Arbutus appoints two new executives

Karen sims, md, phd promoted to chief medical officer christopher naftzger appointed as general counsel and chief compliance officer warminster, pa., july 10, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of dr. karen sims as chief medical officer and mr.
ABUS Ratings Summary
ABUS Quant Ranking